Hoffmann-la Roche Inc.

Roche Palo Alto LLC

Syntex (u.s.a.) Inc.

Chugai Pharmaceutical Co.

Ro&cacute;he Palo Alto LLC

F. Hoffmann-la Roche Ag

Francisco Javier Lopez-Tapia

Counde O'Yang

Sung-Sau So

Christine E Brotherton-Pleiss

Yan Lou

Romyr Dominique

Alam Jahangir

Keith Adrian Murray Walker

Dov Nitzan

Alexander Victor Muehldorf

Robin D Clark

Thomas Weitao Sun

Shu-Hai Zhao

Joan Marie Caroon

Bruce Andrew Kowalczyk

Keith Roger Bley

Timothy D Owens

Jacob Berger

Qi Qiao

Roland Joseph Billedeau

Rama K Kondru

Saul Jaime-Figueroa

Paul Francis Keitz

Ramona Hilgenkamp

Fariborz Firooznia

Peter Michael Wovkulich

Norman Kong

Buelent Kocer

Steven Joseph Berthel

Stephen Deems Gabriel

Jenny Tan

Xiaochun Han

Lee Edwin Lowrie, Jr

Lucja Orzechowski

David John Morgans, Jr

Yimin Qian

Eric Brian Sjogren

Jurg R Pfister

Jim W Li

Javier De Vicente Fidalgo

Ralph New Harris, Iii

David Bruce Repke

Todd Richard Elworthy

Russell Stephen Stabler

Eric Mertz

Kshitij Chhabilbhai Thakkar

Terrence Joseph Connolly

Nancy Elisabeth Krauss

Angel Guzman

Daniel Lee Severance

Klaus K Weinhardt

Chris Richard Melville

Bradley E Loe

Jutta Wanner

Francisco X Talamas

Eun Kyung Lee

Fernando Padilla

Omar Jose Morales

Pankaj D Rege

Patrick Finbar McGarry

Nicholas John Silvester Huby

Gary W Bantle

Arturo Perez-Medrano

Jr Lee Edwin Lowrie

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient. 

Inhibitors of bruton's tyrosine kinase

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

This application discloses compounds according to generic Formula (I) wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient. 

This application discloses compounds according to generic Formula I: (I) wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

This application discloses compounds according to generic Formula (I) wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient. 

Inhibitors of Bruton's tyrosine kinase

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

Thiazole derivatives as inhibitors of Bruton's tyrosine kinase

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

This application discloses compounds according to generic Formula I: wherein the variables are defined as described herein, and which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Inhibitors of bruton'S tyrosine kinase

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, Y, R, R, and Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

[1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators

Growing community of inventors

Honolulu, HI, United States of America

Francisco Javier Lopez-Tapia